Keene & Associates Inc. Has $136,000 Holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Keene & Associates Inc. trimmed its holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 8.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,935 shares of the company’s stock after selling 2,000 shares during the quarter. Keene & Associates Inc.’s holdings in Lifecore Biomedical were worth $136,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Tower Research Capital LLC TRC bought a new stake in Lifecore Biomedical in the 2nd quarter valued at $60,000. Barclays PLC bought a new stake in shares of Lifecore Biomedical in the second quarter valued at about $87,000. Charles Schwab Investment Management Inc. acquired a new stake in Lifecore Biomedical during the second quarter worth about $101,000. PEAK6 Investments LLC bought a new position in Lifecore Biomedical during the second quarter valued at about $179,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Lifecore Biomedical in the 2nd quarter valued at approximately $254,000. Institutional investors and hedge funds own 83.36% of the company’s stock.

Lifecore Biomedical Stock Down 1.8 %

Shares of LFCR stock traded down $0.11 during mid-day trading on Friday, reaching $6.06. The stock had a trading volume of 106,096 shares, compared to its average volume of 366,617. The firm has a market cap of $183.75 million, a PE ratio of -1.81 and a beta of 1.03. Lifecore Biomedical, Inc. has a one year low of $3.69 and a one year high of $11.45. The firm’s 50 day simple moving average is $7.10 and its 200 day simple moving average is $6.97.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.